IlluminOss announces successful treatment of U.S. patients in trial

ROBERT RABINER, founder of IlluminOss Medical, said the company has
ROBERT RABINER, founder of IlluminOss Medical, said the company has "had tremendously successful results treating complex fractures with the IlluminOss System internationally and are excited to now begin applying it to the treatment of patients with impending and pathologic fractures in our first U.S. trial." / PBN FILE PHOTO/RUPERT WHITELEY

EAST PROVIDENCE – The first two patients in IlluminOss Medical Inc.’s U.S. Lightfix clinical trial for the treatment of impending and pathologic fractures have been successfully treated at the Marshall University Joan C. Edwards School of Medicine.

IlluminOss Medical, a commercial-stage medical device company focused on minimally invasive orthopaedic fracture repair, made the announcement on Tuesday.

The company said the IlluminOss System enables surgeons to create a first-of-its-kind patient-conforming implant providing internal support of bones affected by cancer, and that this approach to orthopedic fracture repair has been used in more than 1,000 patients in Europe.

IlluminOss said the technology features smaller incisions, shorter procedure times and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates. It also allows the patient to return to daily activities more quickly without the hindrance of a hard cast.

- Advertisement -

The treatments at the School of Medicine were done in collaboration with Cabell-Huntington Hospital and the Marshall Clinical Research Center.

Surgeries were performed by Dr. Felix Cheung, associate professor and chief of the Division of Orthopaedic Oncology.

Gene DiPoto, senior vice president of R&D at IlluminOss Medical, worked with Cheung and his team to facilitate the successful treatment of the first U.S. patients.

IlluminOss’ minimally invasive technology allows for fracture fixation through patient-specific intramedullary implants utilizing a light-curable polymer, contained within a balloon catheter.
Cheung utilized IlluminOss’ technology in the treatment of two patients, both of whom had metastatic cancer with pathologic fractures of the humerus.

“We are excited for the opportunity to be the first clinical site in the U.S. to apply IlluminOss’ technology to the treatment of a patient with a complex fracture and the results have been remarkable,” Cheung said in a statement. “The patients were completely stable immediately following the procedure and reported little to no discomfort. Having seen firsthand how effective the IlluminOss System is, I believe the benefits it provides to both the surgeon and the patient have the potential to make it a true game-changer in the way fracture repair can be approached.”

Robert Rabiner, founder and president of IlluminOss Medical, said the company has had “tremendously successful results treating complex fractures with the IlluminOss System internationally.” He said he is excited to now begin applying the system to the treatment of patients with impending and pathologic fractures in the first U.S. trial.

IlluminOss is enrolling patients at other U.S. surgical sites in the Lightfix clinical trial; information can be found HERE.

No posts to display